Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-0184 in Chronic Heart Failure
NCT05659264Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 3
01
Overview
Phase 1, randomised, single-blind trial of mRNA-0184 in chronic heart failure (CHF) (3 arms), sponsored by Moderna Inc. Primary endpoint: Treatment-Emergent Adverse Events. Started Dec 2022; status: completed.
02
Drugs
mRNA-0184
03
Conditions
chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT05659264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659264.